InMed Pharmaceuticals (INM) EPS (Diluted) (QoQ) (2021 - 2026)
InMed Pharmaceuticals (INM) EPS (Diluted) (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.59% |
| Dec 31, 2025 | -17.45% |
| Sep 30, 2025 | 67.38% |
| Jun 30, 2025 | -2,623.78% |
| Mar 31, 2025 | 98.65% |
| Dec 31, 2024 | -34.70% |
| Sep 30, 2024 | 46.60% |
| Jun 30, 2024 | -41.34% |
| Mar 31, 2024 | 3.33% |
| Dec 31, 2023 | 75.68% |
| Sep 30, 2023 | -454.46% |
| Jun 30, 2023 | 77.08% |
| Mar 31, 2023 | 34.23% |
| Dec 31, 2022 | 77.51% |
| Sep 30, 2022 | 71.10% |
| Jun 30, 2022 | -128.55% |
| Mar 31, 2022 | 20.59% |
| Dec 31, 2021 | -25.39% |